Juan Carlos Obaya
Overview
Explore the profile of Juan Carlos Obaya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
102
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arrobas Velilla T, Guijarro C, Campuzano Ruiz R, Pinero M, Valderrama Marcos J, Perez Perez A, et al.
Adv Lab Med
. 2023 Dec;
4(2):138-156.
PMID: 38075943
Cardiovascular diseases (CVD) continue to be the main cause of death in our country. Adequate control of lipid metabolism disorders is a key challenge in cardiovascular prevention that is far...
2.
Arrobas Velilla T, Guijarro C, Campuzano Ruiz R, Pinero M, Valderrama Marcos J, Botana Lopez A, et al.
Nefrologia (Engl Ed)
. 2023 Oct;
43(4):474-483.
PMID: 37813740
Cardiovascular diseases (CVD) continue to be the main cause of death in our country. Adequate control of lipid metabolism disorders is a key challenge in cardiovascular prevention that is far...
3.
Arrobas Velilla T, Guijarro C, Campuzano Ruiz R, Pinero M, Valderrama Marcos J, Perez Perez A, et al.
Rev Clin Esp (Barc)
. 2023 Jun;
223(7):440-449.
PMID: 37302464
Cardiovascular diseases (CVD) continue to be the main cause of death in our country. Adequate control of lipid metabolism disorders is a key challenge in cardiovascular prevention that is far...
4.
Arrobas Velilla T, Guijarro C, Campuzano Ruiz R, Pinero M, Valderrama Marcos J, Botana Lopez A, et al.
Endocrinol Diabetes Nutr (Engl Ed)
. 2023 Jun;
70(7):501-510.
PMID: 37268528
Cardiovascular diseases (CVD) continue to be the main cause of death in our country. Adequate control of lipid metabolism disorders is a key challenge in cardiovascular prevention that is far...
5.
Arrobas Velilla T, Guijarro C, Campuzano Ruiz R, Pinero M, Valderrama Marcos J, Perez Perez A, et al.
Clin Investig Arterioscler
. 2023 Mar;
35(2):91-100.
PMID: 36925360
Cardiovascular diseases (CVD) continue to be the main cause of death in our country. Adequate control of lipid metabolism disorders is a key challenge in cardiovascular prevention that is far...
6.
Gorgojo-Martinez J, Mezquita-Raya P, Carretero-Gomez J, Castro A, Cebrian-Cuenca A, de Torres-Sanchez A, et al.
J Clin Med
. 2023 Jan;
12(1).
PMID: 36614945
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are indicated in type 2 diabetes and obesity for their high efficacy in controlling glycaemia and inducing body weight loss, respectively. Patients may develop...
7.
Castaneda S, Gonzalez C, Villaverde V, Lajas Petisco C, Castro M, Jirout F, et al.
Reumatol Clin (Engl Ed)
. 2022 Feb;
18(2):114-123.
PMID: 35153034
Objective: To develop and assess the feasibility in daily practice of four comorbidity checklists, for common use in rheumatoid arthritis (RA), axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA). Methods: A...
8.
Arrieta F, Pedro-Botet J, Iglesias P, Obaya J, Montanez L, Maldonado G, et al.
Clin Investig Arterioscler
. 2021 Jul;
34(1):36-55.
PMID: 34330545
This document is an update to the clinical practice recommendations for the management of cardiovascular risk factors (CVRF) in diabetes mellitus. The consensus has been developed by a multidisciplinary team...
9.
Castaneda S, Gonzalez C, Villaverde V, Lajas Petisco C, Castro M, Jirout F, et al.
Reumatol Clin (Engl Ed)
. 2020 Dec;
PMID: 33293243
Objective: To develop and assess the feasibility in daily practice of four comorbidity checklists, for common use in rheumatoid arthritis (RA), axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA). Methods: A...
10.
Barrios V, Escobar C, Gamarra J, Obaya J, Pallares V
Semergen
. 2020 Dec;
47(1):28-37.
PMID: 33268266
Objective: To ascertain the opinion of physicians about diagnostic criteria, control targets, control rates, and therapeutic approach of patients with dyslipidaemia in Spain. Methods: A specific questionnaire was created about...